Suppr超能文献

皮质 Florbetapir-PET 淀粉样蛋白负荷在前驱期阿尔茨海默病患者中。

Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients.

机构信息

INSERM, Imagerie Cérébrale et Handicaps Neurologiques UMR 825, Centre Hospitalier Universitaire de Toulouse, Place Dr Baylac, Pavillon Baudot, Toulouse CEDEX 9 31059, France.

出版信息

EJNMMI Res. 2013 Jun 3;3(1):43. doi: 10.1186/2191-219X-3-43.

Abstract

BACKGROUND

Florbetapir (AV-45) has been shown to be a reliable tool to assess amyloid load in patients with Alzheimer's disease (AD) at demential stages. Longitudinal studies also suggest that AV-45 has the ability to bind amyloid in the early stages of AD. In this study, we investigated AV-45 binding and its relation with cognitive performance in a group of patients at the prodromal stage of Alzheimer's disease, recruited according to strict inclusion criteria.

METHODS

We recruited patients at the prodromal stage of AD and matched control subjects. AV-45 binding was assessed using an innovative extraction method allowing quantifying uptake in the cortex only. AV-45 uptake was compared between groups in the precuneus, posterior cingulate, anterior cingulate, and orbito-frontal regions. Correlations between AV-45 uptake and cognitive performance were assessed.

RESULTS

Twenty-two patients and 17 matched control subjects were included in the study. We report a significant increase of cortical AV-45 uptake in the patients compared to the control subjects in all regions of interest. Specific correlations were found within the patient group between mean global amyloid cortical load and cognitive performance in three different memory tests.

CONCLUSIONS

These findings suggest that at the prodromal stage of AD, memory decline is linked to an increase of cortical β-amyloid load.

摘要

背景

氟比洛芬(AV-45)已被证明是一种可靠的工具,可以评估痴呆阶段阿尔茨海默病(AD)患者的淀粉样蛋白负荷。纵向研究还表明,AV-45 有能力在 AD 的早期阶段结合淀粉样蛋白。在这项研究中,我们根据严格的纳入标准,在一组处于 AD 前驱期的患者中,调查了 AV-45 的结合及其与认知表现的关系。

方法

我们招募了处于 AD 前驱期的患者和匹配的对照组。使用一种创新的提取方法评估 AV-45 结合,该方法仅允许定量评估皮质中的摄取。在楔前叶、后扣带、前扣带和眶额区域比较组间 AV-45 摄取。评估 AV-45 摄取与认知表现之间的相关性。

结果

22 名患者和 17 名匹配的对照组被纳入研究。我们报告说,与对照组相比,患者的所有感兴趣区域的皮质 AV-45 摄取均显著增加。在患者组中,还发现了特定的相关性,即平均全局淀粉样蛋白皮质负荷与三种不同记忆测试中的认知表现之间的相关性。

结论

这些发现表明,在 AD 的前驱期,记忆下降与皮质β-淀粉样蛋白负荷的增加有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab62/3733998/ca447ee7a4ec/2191-219X-3-43-1.jpg

相似文献

1
Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients.
EJNMMI Res. 2013 Jun 3;3(1):43. doi: 10.1186/2191-219X-3-43.
2
Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.
Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):621-31. doi: 10.1007/s00259-011-2021-8. Epub 2012 Jan 18.
4
Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo.
Eur J Nucl Med Mol Imaging. 2014 May;41(5):836-43. doi: 10.1007/s00259-013-2656-8. Epub 2013 Dec 19.
6
Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography.
Am J Geriatr Psychiatry. 2013 Mar;21(3):272-8. doi: 10.1016/j.jagp.2012.11.016.
8
Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
J Int Neuropsychol Soc. 2016 Nov;22(10):978-990. doi: 10.1017/S1355617716000928.

引用本文的文献

1
Neuron-Targeted Exosome Therapy: A Novel Approach for Treating Cardiogenic Dementia via RyR2 Inhibition.
Med Hypotheses. 2024 Feb;183. doi: 10.1016/j.mehy.2024.111266. Epub 2024 Jan 9.
2
X chromosome-wide association study of quantitative biomarkers from the Alzheimer's Disease Neuroimaging Initiative study.
Front Aging Neurosci. 2023 Nov 14;15:1277731. doi: 10.3389/fnagi.2023.1277731. eCollection 2023.
3
MRAβ: A multimodal MRI-derived amyloid-β biomarker for Alzheimer's disease.
Hum Brain Mapp. 2023 Oct 15;44(15):5139-5152. doi: 10.1002/hbm.26452. Epub 2023 Aug 14.
4
miRNAs and Stem Cells as Promising Diagnostic and Therapeutic Targets for Alzheimer's Disease.
J Alzheimers Dis. 2023;94(s1):S203-S225. doi: 10.3233/JAD-221298.
5
6
Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease.
Neurobiol Aging. 2021 Oct;106:119-129. doi: 10.1016/j.neurobiolaging.2021.06.014. Epub 2021 Jun 21.
7
Optical Coherence Tomography in Patients with Alzheimer's Disease: What Can It Tell Us?
Eye Brain. 2021 Jan 8;13:1-20. doi: 10.2147/EB.S235238. eCollection 2021.
10
Amyloid and FDG PET of Successful Cognitive Aging: Global and Cingulate-Specific Differences.
J Alzheimers Dis. 2018;66(1):307-318. doi: 10.3233/JAD-180360.

本文引用的文献

1
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
Lancet Neurol. 2013 Apr;12(4):357-67. doi: 10.1016/S1474-4422(13)70044-9. Epub 2013 Mar 8.
2
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.
Alzheimers Dement. 2013 Oct;9(5 Suppl):S72-83. doi: 10.1016/j.jalz.2012.10.007. Epub 2013 Jan 30.
3
5
Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.
J Neurol Neurosurg Psychiatry. 2012 Sep;83(9):923-6. doi: 10.1136/jnnp-2012-302548. Epub 2012 Jul 11.
6
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Neurology. 2012 Oct 16;79(16):1636-44. doi: 10.1212/WNL.0b013e3182661f74. Epub 2012 Jul 11.
8
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease.
Neurobiol Aging. 2013 Jan;34(1):1-12. doi: 10.1016/j.neurobiolaging.2012.04.017. Epub 2012 May 24.
9
MR, (18)F-FDG, and (18)F-AV45 PET correlate with AD PSEN1 original phenotype.
Alzheimer Dis Assoc Disord. 2013 Jan-Mar;27(1):91-4. doi: 10.1097/WAD.0b013e318251d87c.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验